US ▾
CSBR
Earnings call · Jul 2026 (Q1 FY27)

CHAMPIONS ONCOLOGY Q1 FY27 earnings call CSBR

Sep 10, 2026 Source

Executive summary

Champions Oncology Q1 FY27 — Strong Revenue Growth and Margin Expansion

Champions Oncology delivered strong Q1 FY27 results, demonstrating the payoff from prior investments with significant revenue growth and margin expansion across both its translational oncology services and data licensing businesses. The company achieved its fifth consecutive quarter of positive adjusted EBITDA, driven by operational discipline and in-house cost efficiencies. Management remains encouraged by the robust pipeline and strategic strengthening of its data offerings, with a focus on continued profitability improvement.

Highlights

5

  • Revenue increased by approximately 9% to $15.2 million in Q1 FY27.

  • Gross margin improved significantly to 50% in Q1 FY27, up from 43% in Q1 FY26.

  • Adjusted EBITDA reached $671,000, marking the fifth consecutive quarter of positive adjusted EBITDA.

  • Data licensing revenue grew substantially to $893,000 in Q1 FY27, exceeding all of fiscal 2026.

  • Oncology services margin improved to 51% from 43% YoY, driven by cost reduction and operating leverage.

Segment performance

SegmentRevenueYoYQoQMargin
Translational Oncology Services
Margin improved from 43% in Q1 FY26. Demand environment is healthy, driven by the quality of the tumor bank. Operating discipline contributed to margin hold.
$14.3 million——51%
Data Licensing
Generated more revenue in Q1 FY27 than in all of fiscal 2026. Revenue will remain lumpy due to contract timelines. Broader customer base built last year.
$893,000———

What to watch in Q2 FY27

Corellia funding/partnership

Next quarter/Fiscal '27
Current External conversations ongoing
Target Secured outside funding or licensing partnership

Why it matters

Securing external funding or a partnership for Corellia would allow for the redeployment of investment to other growth initiatives and the bottom line, impacting overall profitability.

If we're successful in securing outside funding or a licensing partnership, the investment currently flowing into that business would be redeployed toward our other growth initiatives, particularly data and to the bottom line.

2 min read 6 chapters

Detailed narrative

Investment Payoff and Operational Discipline

Management highlighted that fiscal 2026 was an investment year, and the first quarter of fiscal 2027 provides strong evidence that these investments are paying off. The company demonstrated improved revenue and margins, attributing this success to operational discipline. This focus on efficiency was particularly evident in the translational oncology services business, contributing to overall financial improvement.

Translational Oncology Services (TOS) Performance

The translational oncology services business generated $14.3 million in revenue during the quarter. Margins in this segment were maintained at desired levels, reaching 51%, up from 43% in the prior year quarter. The demand environment for their predictive modeling services remains healthy, with the quality of their tumor bank cited as a core reason for customer engagement.

Significant Growth in Data Licensing Revenue

Data licensing revenue reached $893,000 in the first quarter, a substantial increase that surpassed the total data revenue generated in all of fiscal 2026. This growth reflects the broader customer base built over the past year. The company emphasizes the strategic importance of its deeply characterized, clinically annotated, patient-derived data for supporting AI and machine learning applications in drug development, despite acknowledging the inherent lumpiness of contract-based revenue.

Corellia Therapeutic Subsidiary Progress

Champions Oncology remains encouraged by the progress of Corellia, its wholly-owned therapeutic subsidiary. External conversations are ongoing with both venture groups and potential pharmaceutical partners, with generated data continuing to strengthen the case for the asset. Management indicated that if successful in securing outside funding or a licensing partnership, the investment currently allocated to Corellia would be redeployed towards other growth initiatives, particularly data, and to the bottom line.

Cost Structure Optimization and Margin Improvement

A key driver of the improved oncology services margin was a reduction in the cost of oncology revenue, which declined by approximately $500,000 to $7.5 million from $8 million a year ago. This reduction was primarily due to lower third-party radiolabeling costs, as the company has been working to bring these capabilities in-house. This internal optimization contributed significantly to the overall margin expansion.

Strategic Sales and Marketing Investment

Sales and marketing expense increased to $3 million from $1.8 million in the prior year quarter. This was a deliberate investment made last year to expand the commercial organization across both research services and data businesses. The company's current focus is on leveraging this expanded base to generate greater revenue and profitability, demonstrating the expected returns from this strategic expenditure.

AI-generated summary of the company's earnings call. Not investment advice.